1
|
Liu KJ, Wu HY. A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer. Oncotarget 2016; 6:22750-7. [PMID: 26093089 PMCID: PMC4673196 DOI: 10.18632/oncotarget.4262] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2015] [Accepted: 05/30/2015] [Indexed: 11/25/2022] Open
Abstract
Patients with non-small-cell lung cancer (NSCLC) often have an advanced disease when firstly diagnosed. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor receptor (VEGFR). In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. Results showed that the objective response rate(ORR) of this novel regimen is 43%, median progression-free survival (PFS) was 5.2 months (95% CI, 3.7 to 6.7 months) and median overall survival (OS) was 11.4 months (95% CI, 8.8 to 13.9 months). Adverse events were generally mild, ranging from grade 1 to grade 3. In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. Randomized clinical trials are needed to further investigate the efficacy of this regimen.
Collapse
Affiliation(s)
- Ke-Jun Liu
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.,Department of Medical Oncology, Dongguan People's Hospital, Dongguan, China
| | - Hai-Ying Wu
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China
| |
Collapse
|
2
|
Ma Q, Min K, Wang T, Chen B, Wen Q, Wang F, Ji T, Gao S. 99mTc-3PRGD2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab. Ann Nucl Med 2015; 29:519-27. [DOI: 10.1007/s12149-015-0975-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2015] [Accepted: 04/12/2015] [Indexed: 10/23/2022]
|
3
|
Mou W, Xue H, Tong H, Sun S, Zhang Z, Zhang C, Sun Q, Dong J, Wen X, Yan G, Tian Y. Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy. Oncol Lett 2014; 7:2073-2078. [PMID: 24932291 PMCID: PMC4049753 DOI: 10.3892/ol.2014.1988] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2013] [Accepted: 03/04/2014] [Indexed: 12/30/2022] Open
Abstract
Cisplatin/pemetrexed chemotherapy has been established as a standard treatment in lung adenocarcinoma. However, the response to the cisplatin/pemetrexed combination varies considerably among patients due to individual variations. Thus, novel biomarkers are required to aid the prediction of the response to the cisplatin/pemetrexed combination. We hypothesized that leptin expression may be a determinant for prognosis in lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy. Serum from consenting patients with lung adenocarcinoma were obtained for the measurement of leptin and associated tumor biomarkers. Leptin expression was measured by radioimmunoassay. Carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA15-3, CA125, CA72-4, cytokeratin 19 fragment (CYFRA21-1) and neuron-specific enolase (NSE) expression were determined by electrochemiluminescence immunoassays. Serum squamous cell carcinoma antigen levels were measured using a microparticle enzyme immunoassay. The associations between serum leptin and tumor biomarker expression were evaluated by Spearman's correlation analysis. Serum CEA, CA19-9, CA15-3, CA125, CA72-4, CYFRA21-1 and NSE levels showed no obvious difference among patients. However, a trend towards an improved prognosis was observed in patients with lower serum leptin at diagnosis and an increase during cisplatin/pemetrexed chemotherapy. The results indicated that the serum leptin level has prognostic indications in patients with advanced lung adenocarcinoma during cisplatin/pemetrexed chemotherapy, which indicates that it may be a useful marker for the prognosis of cancer patients undergoing chemotherapy treatment.
Collapse
Affiliation(s)
- Wenjun Mou
- School of Medicine, Nankai University, Tianjin 300071, P.R. China ; Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Hui Xue
- Research Laboratory of Biochemistry, Basic Medical Institute, Beijing 100853, P.R. China
| | - Hongli Tong
- Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Shengjie Sun
- Oncology Department, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Zhuhong Zhang
- School of Medicine, Nankai University, Tianjin 300071, P.R. China ; Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Chunyan Zhang
- School of Medicine, Nankai University, Tianjin 300071, P.R. China ; Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Qiyu Sun
- Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Jing Dong
- Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Xinyu Wen
- Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China
| | - Guangtao Yan
- Research Laboratory of Biochemistry, Basic Medical Institute, Beijing 100853, P.R. China
| | - Yaping Tian
- School of Medicine, Nankai University, Tianjin 300071, P.R. China ; Department of Clinical Biochemistry, Chinese PLA General Hospital, Beijing 100853, P.R. China
| |
Collapse
|